ClinicalTrials.gg
TerminatedNCT00642941Updated Feb 3, 2021Results posted

A Study of R1507 in Participants With Recurrent or Refractory Sarcoma

A Phase 2 interventional study of RG1507 in Sarcoma, sponsored by Hoffmann-La Roche. Terminated at 41 sites in 11 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2021-02-03.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was closed to further enrollment due to the decision by the Sponsor to discontinue development of R1507.

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Dec 2007, registered Mar 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
317
Allocation
Non-randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 958 studies in Sarcoma with a site in United States — 153 open to participants now, 244 under way, 4 of them phase 3. Sarcoma · United States.

Enrollment
35th of 800
317 · median 35
Started
2007
with 31 others
Phase 2
310 of 958
30 open now
Registered
282nd of 958
by date

Among the 958 studies in Sarcoma with a site in United States, this one is the 35th largest by enrollment of the 800 interventional ones that give a count, is one of 32 that started in 2007, is one of 310 in phase 2, and was the 282nd registered.

Sarcoma

1,609 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

153 of the 958 studies in Sarcoma with a site in United States are open now. Recruiting first, the newest first:

148 more — sign in →

All 153 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 93 take children under 18; 12 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 958 studies in Sarcoma with a site in United States, or all of them as a file.
02

Study summary

The study was primarily designed to determine objective response, progression-free survival (PFS), and the safety and tolerability of R1507 in participants with recurrent or refractory Ewing's sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma and other sarcomas including alveolar soft part sarcoma, desmoplastic small round cell tumor, extraskeletal myxoid chondrosarcoma, clear cell sarcoma, and myxoid liposarcoma.

03

Conditions studied

  • Sarcoma

Browse trials for

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • progressive, recurrent or Ewing's sarcoma, or recurrent or refractory osteosarcoma, synovial sarcoma, rhabdomyosarcoma, or other sarcomas of the following sub-types: alveolar soft part sarcoma, desmoplastic small round cell tumor, extraskeletal myxoid chondrosarcoma, clear cell sarcoma and myxoid liposarcoma;
  • Cohort 3 only: age must be >= 2 and \<= 21 years

Exclusion criteria

Exclusion Criteria:

  • unrelated systemic illness which would compromise the participant's ability to tolerate the agent, or interfere with the study procedures or results;
  • known to any of the components of R1507 or prior hypersensitivity reactions to monoclonal antibodies;
  • treatment (within the past 2 weeks) with pharmacologic doses of or other agents;
  • current or prior therapy with insulin-like growth factor (IGF) inhibitor (monoclonal or specific kinase inhibitor);
  • history of solid organ transplant;
  • other malignant disease diagnosed within the previous 5 years, excluding intra-epithelial cervical neoplasia or non-melanoma skin cancer;
  • active central nervous system disease
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
317 participants (actual)

Study arms

  • Experimental
    Cohort 1: Ewings Sarcoma Primary Cohort

    Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.

    Drug: RG1507

  • Experimental
    Cohort 2: Ewings Sarcoma Secondary Cohort

    Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.

    Drug: RG1507

  • Experimental
    Cohort 3: Ewings Sarcoma Expanded Cohort

    Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.

    Drug: RG1507

  • Experimental
    Cohort 4: Osteosarcoma

    Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.

    Drug: RG1507

  • Experimental
    Cohort 5: Synovial Sarcoma

    Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.

    Drug: RG1507

  • Experimental
    Cohort 6: Rhabdomyosarcoma

    Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.

    Drug: RG1507

  • Experimental
    Cohort 7a: Alveolar Soft Part Sarcoma

    Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a includes individuals with alveolar soft part sarcoma.

    Drug: RG1507

  • Experimental
    Cohort 7b: Desmoplastic Small Round Cell Tumors.

    Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.

    Drug: RG1507

  • Experimental
    Cohort 7c: Extraskeletal Myxoid Chondrosarcoma

    Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.

    Drug: RG1507

  • Experimental
    Cohort 7d: Clear Cell Sarcoma

    Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.

    Drug: RG1507

  • Experimental
    Cohort 7e: Myxoid Liposarcoma

    Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.

    Drug: RG1507

  • Experimental
    Cohort 8: Diagnosis Not Specified

    Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.

    Drug: RG1507

Interventions

  • DrugRG1507

    Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Complete or Partial Response, According to World Health Organization (WHO) Criteria in Cohorts 2 to 8

    Complete response is the disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart. Partial response is \>=50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive.

    Time frame: Baseline up to 6 years (assessed at baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression)

  2. Progression-Free Survival (PFS) Rate According to WHO Response Criteria at 18 Weeks From Start of R2607 Treatment in Cohort 1

    The PFS survival rate is a landmark analysis of progression-free survival at 18 weeks from start of treatment. Progression-free survival rate at 18 weeks is a dichotomous endpoint, with a patient categorized as alive (with either stable disease or objective response) at 18 weeks from start of treatment.

    Time frame: Baseline up to 18 weeks (assessed at baseline, every 6 weeks until disease progression)

  3. Percentage of Participants With Adverse Events (AEs) in Cohort 1 and 2

    Time frame: Baseline up to 6 years

Secondary outcomes

  1. Percentage of Participants With Complete or Partial Response According to WHO Response Criteria in Cohort 1

    Complete response is the disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart. Partial response is \>=50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive.

    Time frame: Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)

  2. PFS Rate According to WHO Response Criteria at 18 Weeks From Start of R1507 Treatment in Cohorts 2 to 8

    The PFS survival rate is a landmark analysis of progression-free survival at 18 weeks from start of treatment. Progression-free survival rate at 18 weeks is a dichotomous endpoint, with a patient categorized as alive (with either stable disease or objective response at 18 weeks) from start of treatment.

    Time frame: Baseline, every 6 weeks until disease progression (up to 18 weeks)

  3. Percentage of Participants With AEs in Cohorts 3-8

    Time frame: Baseline up to 6 years

  4. Duration of Response (DOR) According to WHO Response Criteria in Cohorts 1 to 8

    The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented. Complete response is the disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart. Partial response is \>=50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive.

    Time frame: Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)

  5. Time to Progression (TTP) According to WHO Response Criteria in Cohorts 1 to 8

    TTP is defined as the time from date of randomization until objective tumor progression. According to the WHO Response Criteria, objective tumor progression is \> 25% increase in the area of one or more measurable lesions or the appearance of new lesions.

    Time frame: Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)

  6. Failure-Free Survival (FFS) According to WHO Response Criteria in Cohorts 1 to 8

    FFS was measured from the date of treatment start to the date of documented disease progression, relapse, or death from any cause.

    Time frame: Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)

  7. Overall Survival (OS) in Cohorts 1 to 8

    OS was measured from the time of study registration to the date of death or was censored at the date of last contact.

    Time frame: Baseline until death (up to 6 years)

  8. PFS According to WHO Response Criteria in Cohorts 1 to 8

    PFS is defined as the duration of time from start of treatment to time of objective progression or death.

    Time frame: Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)

  9. Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of R1507

    Time frame: Predose (0 hours [h]), end of 60-90 minutes infusion (EOI), postdose (2, 24, 72-96 h) in Week 1; predose (0 h) and EOI in Weeks 2, 4, 6, 9; predose (0 h), EOI, postdose (48 h) in Week 12; predose (0 h) in Week 13, at final visit (up to 6 years)

  10. Pharmacokinetics: Clearance (CL) of R1507

    Time frame: Predose (0 h), EOI (infusion over 60-90 minutes), postdose (2, 24, 72-96 h) in Week 1; predose (0 h) and EOI in Weeks 2, 4, 6, 9; predose (0 h), EOI, postdose (48 h) in Week 12; predose (0 h) in Week 13, at final visit (up to 6 years)

07

Results

Posted Feb 3, 2021
Limitations and caveats
The study was closed to further enrollment due to a decision by the Sponsor to discontinue development of R1507. The decision was made based upon available data from other completed/ongoing trials of R1507 and was not due to safety concerns.

Participant flow

A screening period was included prior to administration of study drug. Tumor scans/X-rays were to be obtained within 4 weeks, fluro-D-glucose positron emission tomography (FDG-PET) scans within 2 weeks, and Baseline laboratory evaluations within 1 week before first dose.

Participant flow — Overall Study
MilestoneCohort 1: Ewings Sarcoma Primary CohortCohort 2: Ewings Sarcoma Secondary CohortCohort 3: Ewings Sarcoma Expanded CohortCohort 4: OsteosarcomaCohort 5: Synovial SarcomaCohort 6: RhabdomyosarcomaCohort 7a: Alveolar Soft Part SarcomaCohort 7b: Desmoplastic Small Round Cell Tumors.Cohort 7c: Extraskeletal Myxoid ChondrosarcomaCohort 7d: Clear Cell SarcomaCohort 7e: Myxoid LiposarcomaCohort 8: Diagnosis Not Specified
Started7054740254123141191211
Completed000000000000
Not completed7054740254123141191211
Withdrew: Physician decision310000100101
Withdrew: Death401121000001
Withdrew: Study closed by sponsor010000000000
Withdrew: Withdrawal by subject100200201001
Withdrew: Protocol violation000000100000
Withdrew: Adverse event110000110100
Withdrew: Other111101010001
Withdrew: Disease progression605053623391812107127

Outcome measures

PrimaryPercentage of Participants With Complete or Partial Response, According to World Health Organization (WHO) Criteria in Cohorts 2 to 8

Complete response is the disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart. Partial response is \>=50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive.

Time frame:
Baseline up to 6 years (assessed at baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Complete or Partial Response, According to World Health Organization (WHO) Criteria in Cohorts 2 to 8
Percentage of ParticipantsCohort 2: Ewings Sarcoma Secondary CohortCohort 3: Ewings Sarcoma Expanded CohortCohort 4: OsteosarcomaCohort 5: Synovial SarcomaCohort 6: RhabdomyosarcomaCohort 7a: Alveolar Soft Part SarcomaCohort 7b: Desmoplastic Small Round Cell Tumors.Cohort 7c: Extraskeletal Myxoid ChondrosarcomaCohort 7d: Clear Cell SarcomaCohort 7e: Myxoid LiposarcomaCohort 8: Diagnosis Not Specified
Percentage of Participants With Complete or Partial Response, According to World Health Organization (WHO) Criteria in Cohorts 2 to 811.11—2.54.04.88000000
PrimaryProgression-Free Survival (PFS) Rate According to WHO Response Criteria at 18 Weeks From Start of R2607 Treatment in Cohort 1

The PFS survival rate is a landmark analysis of progression-free survival at 18 weeks from start of treatment. Progression-free survival rate at 18 weeks is a dichotomous endpoint, with a patient categorized as alive (with either stable disease or objective response) at 18 weeks from start of treatment.

Time frame:
Baseline up to 18 weeks (assessed at baseline, every 6 weeks until disease progression)
Reported as:
Number · Percentage of Participants
Progression-Free Survival (PFS) Rate According to WHO Response Criteria at 18 Weeks From Start of R2607 Treatment in Cohort 1
Percentage of ParticipantsCohort 1: Ewings Sarcoma Primary Cohort
Progression-Free Survival (PFS) Rate According to WHO Response Criteria at 18 Weeks From Start of R2607 Treatment in Cohort 115.81
PrimaryPercentage of Participants With Adverse Events (AEs) in Cohort 1 and 2
Time frame:
Baseline up to 6 years
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) in Cohort 1 and 2
percentage of participantsCohort 1: Ewings Sarcoma Primary CohortCohort 2: Ewings Sarcoma Secondary Cohort
Percentage of Participants With Adverse Events (AEs) in Cohort 1 and 29696
SecondaryPercentage of Participants With Complete or Partial Response According to WHO Response Criteria in Cohort 1

Complete response is the disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart. Partial response is \>=50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive.

Time frame:
Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete or Partial Response According to WHO Response Criteria in Cohort 1
percentage of participantsCohort 1: Ewings Sarcoma Primary Cohort
Percentage of Participants With Complete or Partial Response According to WHO Response Criteria in Cohort 18.57
SecondaryPFS Rate According to WHO Response Criteria at 18 Weeks From Start of R1507 Treatment in Cohorts 2 to 8

The PFS survival rate is a landmark analysis of progression-free survival at 18 weeks from start of treatment. Progression-free survival rate at 18 weeks is a dichotomous endpoint, with a patient categorized as alive (with either stable disease or objective response at 18 weeks) from start of treatment.

Time frame:
Baseline, every 6 weeks until disease progression (up to 18 weeks)
Reported as:
Number · Percentage of Participants
PFS Rate According to WHO Response Criteria at 18 Weeks From Start of R1507 Treatment in Cohorts 2 to 8
Percentage of ParticipantsCohort 2: Ewings Sarcoma Secondary CohortCohort 3: Ewings Sarcoma Expanded CohortCohort 4: OsteosarcomaCohort 5: Synovial SarcomaCohort 6: RhabdomyosarcomaCohort 7a: Alveolar Soft Part SarcomaCohort 7b: Desmoplastic Small Round Cell Tumors.Cohort 7c: Extraskeletal Myxoid ChondrosarcomaCohort 7e: Myxoid LiposarcomaCohort 7d: Clear Cell SarcomaCohort 8: Diagnosis Not Specified
PFS Rate According to WHO Response Criteria at 18 Weeks From Start of R1507 Treatment in Cohorts 2 to 817.16—19.694.007.3245.408.1662.3408.3322.86
SecondaryPercentage of Participants With AEs in Cohorts 3-8
Time frame:
Baseline up to 6 years
Reported as:
Number · percentage of participants
Percentage of Participants With AEs in Cohorts 3-8
percentage of participantsCohort 3: Ewings Sarcoma Expanded CohortCohort 4: OsteosarcomaCohort 5: Synovial SarcomaCohort 6: RhabdomyosarcomaCohort 7a: Alveolar Soft Part SarcomaCohort 7b: Desmoplastic Small Round Cell Tumors.Cohort 7c: Extraskeletal Myxoid ChondrosarcomaCohort 7d: Clear Cell SarcomaCohort 7e: Myxoid LiposarcomaCohort 8: Diagnosis Not Specified
Percentage of Participants With AEs in Cohorts 3-885.7100100959186100100100100
SecondaryDuration of Response (DOR) According to WHO Response Criteria in Cohorts 1 to 8

The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented. Complete response is the disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart. Partial response is \>=50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive.

Time frame:
Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)
Reported as:
Median · weeks
Duration of Response (DOR) According to WHO Response Criteria in Cohorts 1 to 8
weeksCohort 1: Ewings Sarcoma Primary CohortCohort 2: Ewings Sarcoma Secondary CohortCohort 3: Ewings Sarcoma Expanded CohortCohort 4: OsteosarcomaCohort 5: Synovial SarcomaCohort 6: RhabdomyosarcomaCohort 7a: Alveolar Soft Part SarcomaCohort 7b: Desmoplastic Small Round Cell Tumors.Cohort 7c: Extraskeletal Myxoid ChondrosarcomaCohort 7d: Clear Cell SarcomaCohort 7e: Myxoid LiposarcomaCohort 8: Diagnosis Not Specified
Duration of Response (DOR) According to WHO Response Criteria in Cohorts 1 to 844.29 (18 to NA)42.86 (18.14 to NA)—NA (30.14 to NA)13.14 (13.14 to NA)NA (21 to NA)——————
SecondaryTime to Progression (TTP) According to WHO Response Criteria in Cohorts 1 to 8

TTP is defined as the time from date of randomization until objective tumor progression. According to the WHO Response Criteria, objective tumor progression is \> 25% increase in the area of one or more measurable lesions or the appearance of new lesions.

Time frame:
Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)
Reported as:
Median · weeks
Time to Progression (TTP) According to WHO Response Criteria in Cohorts 1 to 8
weeksCohort 1: Ewings Sarcoma Primary CohortCohort 2: Ewings Sarcoma Secondary CohortCohort 3: Ewings Sarcoma Expanded CohortCohort 4: OsteosarcomaCohort 5: Synovial SarcomaCohort 6: RhabdomyosarcomaCohort 7a: Alveolar Soft Part SarcomaCohort 7b: Desmoplastic Small Round Cell Tumors.Cohort 7c: Extraskeletal Myxoid ChondrosarcomaCohort 7d: Clear Cell SarcomaCohort 7e: Myxoid LiposarcomaCohort 8: Diagnosis Not Specified
Time to Progression (TTP) According to WHO Response Criteria in Cohorts 1 to 86.00 (5.29 to 9.71)6.00 (5.71 to 8.14)—5.71 (5.57 to 7.00)6.00 (5.57 to 6.43)5.50 (5.14 to 6.14)11.14 (6.00 to 17.71)6.14 (5.86 to 11.14)18.00 (5.71 to NA)5.57 (5.14 to 5.86)5.86 (5.29 to 8.43)6.14 (5.86 to 10.00)
SecondaryFailure-Free Survival (FFS) According to WHO Response Criteria in Cohorts 1 to 8

FFS was measured from the date of treatment start to the date of documented disease progression, relapse, or death from any cause.

Time frame:
Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)

No measurements were reported for this outcome.

SecondaryOverall Survival (OS) in Cohorts 1 to 8

OS was measured from the time of study registration to the date of death or was censored at the date of last contact.

Time frame:
Baseline until death (up to 6 years)
Reported as:
Median · weeks
Overall Survival (OS) in Cohorts 1 to 8
weeksCohort 1: Ewings Sarcoma Primary CohortCohort 2: Ewings Sarcoma Secondary CohortCohort 3: Ewings Sarcoma Expanded CohortCohort 4: OsteosarcomaCohort 5: Synovial SarcomaCohort 6: RhabdomyosarcomaCohort 7a: Alveolar Soft Part SarcomaCohort 7b: Desmoplastic Small Round Cell Tumors.Cohort 7c: Extraskeletal Myxoid ChondrosarcomaCohort 7d: Clear Cell SarcomaCohort 7e: Myxoid LiposarcomaCohort 8: Diagnosis Not Specified
Overall Survival (OS) in Cohorts 1 to 829.57 (20.57 to 37.57)43.57 (33.29 to 69.00)—37.14 (25.57 to NA)40.71 (21.71 to 64.14)30.86 (21.57 to 50.00)42.43 (42.43 to NA)40.86 (23.57 to NA)NA (NA to NA)17.00 (9.14 to NA)36.00 (33.14 to NA)17.43 (13.00 to 30.14)
SecondaryPFS According to WHO Response Criteria in Cohorts 1 to 8

PFS is defined as the duration of time from start of treatment to time of objective progression or death.

Time frame:
Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)
Reported as:
Median · weeks
PFS According to WHO Response Criteria in Cohorts 1 to 8
weeksCohort 1: Ewings Sarcoma Primary CohortCohort 2: Ewings Sarcoma Secondary CohortCohort 3: Ewings Sarcoma Expanded CohortCohort 4: OsteosarcomaCohort 5: Synovial SarcomaCohort 6: RhabdomyosarcomaCohort 7a: Alveolar Soft Part SarcomaCohort 7b: Desmoplastic Small Round Cell Tumors.Cohort 7c: Extraskeletal Myxoid ChondrosarcomaCohort 7d: Clear Cell SarcomaCohort 7e: Myxoid LiposarcomaCohort 8: Diagnosis Not Specified
PFS According to WHO Response Criteria in Cohorts 1 to 86.00 (5.29 to 9.57)6.00 (5.71 to 8.14)—5.71 (5.57 to 6.43)6.00 (5.43 to 6.14)5.43 (5.14 to 6.14)11.14 (5.71 to 11.71)6.14 (5.86 to 11.14)18.00 (5.71 to NA)5.57 (5.14 to 5.86)5.86 (5.29 to 8.43)6.14 (5.86 to 10)
SecondaryPharmacokinetics: Area Under the Concentration-Time Curve (AUC) of R1507
Time frame:
Predose (0 hours [h]), end of 60-90 minutes infusion (EOI), postdose (2, 24, 72-96 h) in Week 1; predose (0 h) and EOI in Weeks 2, 4, 6, 9; predose (0 h), EOI, postdose (48 h) in Week 12; predose (0 h) in Week 13, at final visit (up to 6 years)

No measurements were reported for this outcome.

SecondaryPharmacokinetics: Clearance (CL) of R1507
Time frame:
Predose (0 h), EOI (infusion over 60-90 minutes), postdose (2, 24, 72-96 h) in Week 1; predose (0 h) and EOI in Weeks 2, 4, 6, 9; predose (0 h), EOI, postdose (48 h) in Week 12; predose (0 h) in Week 13, at final visit (up to 6 years)

No measurements were reported for this outcome.

Adverse events

Collected over Baseline up to 6 years. Non-serious events are listed at a 0.05% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Ewings Sarcoma Primary Cohort9/70 (12.9%)11/70 (15.7%)67/70 (95.7%)
Cohort 2: Ewings Sarcoma Secondary Cohort5/54 (9.3%)13/54 (24.1%)52/54 (96.3%)
Cohort 3: Ewings Sarcoma Expanded Cohort2/7 (28.6%)1/7 (14.3%)6/7 (85.7%)
Cohort 4: Osteosarcoma7/40 (17.5%)4/40 (10%)40/40 (100%)
Cohort 5: Synovial Sarcoma3/25 (12%)5/25 (20%)25/25 (100%)
Cohort 6: Rhabdomyosarcoma3/41 (7.3%)4/41 (9.8%)39/41 (95.1%)
Cohort 7a: Alveolar Soft Part Sarcoma1/23 (4.3%)1/23 (4.3%)21/23 (91.3%)
Cohort 7b: Desmoplastic Small Round Cell Tumors0/14 (0%)1/14 (7.1%)12/14 (85.7%)
Cohort 7c: Extraskeletal Myxoid Chondrosarcoma0/11 (0%)0/11 (0%)11/11 (100%)
Cohort 7d: Clear Cell Sarcoma1/9 (11.1%)3/9 (33.3%)9/9 (100%)
Cohort 7e: Myxoid Liposarcoma1/12 (8.3%)2/12 (16.7%)12/12 (100%)
Cohort 8: Diagnosis Not Specified2/11 (18.2%)4/11 (36.4%)11/11 (100%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventCohort 1: Ewings Sarcoma Primary CohortCohort 2: Ewings Sarcoma Secondary CohortCohort 3: Ewings Sarcoma Expanded CohortCohort 4: OsteosarcomaCohort 5: Synovial SarcomaCohort 6: RhabdomyosarcomaCohort 7a: Alveolar Soft Part SarcomaCohort 7b: Desmoplastic Small Round Cell TumorsCohort 7c: Extraskeletal Myxoid ChondrosarcomaCohort 7d: Clear Cell SarcomaCohort 7e: Myxoid LiposarcomaCohort 8: Diagnosis Not Specified
Pleural effusionRespiratory, thoracic and mediastinal disorders0/700/541/70/400/250/410/230/140/110/90/120/11
PyrexiaGeneral disorders0/700/540/70/400/250/410/230/140/111/90/120/11
Intestinal perforationGastrointestinal disorders0/700/540/70/400/250/410/230/140/111/90/120/11
VomitingGastrointestinal disorders0/701/540/70/400/250/410/230/140/111/90/120/11
Respiratory failureRespiratory, thoracic and mediastinal disorders0/700/540/70/400/250/410/230/140/110/90/121/11
ConstipationGastrointestinal disorders0/701/540/70/400/250/410/230/140/110/90/121/11
Neck painMusculoskeletal and connective tissue disorders0/700/540/70/400/250/410/230/140/110/90/121/11
Pain in extremityMusculoskeletal and connective tissue disorders0/700/540/70/400/250/410/230/140/110/90/121/11
Escherichia sepsisInfections and infestations0/700/540/70/400/250/410/230/140/110/91/120/11
Staphylococcal infectionInfections and infestations0/700/540/70/400/250/410/230/140/110/91/120/11
Most frequent other events
Showing 10 of 193
Most frequent other events
EventCohort 1: Ewings Sarcoma Primary CohortCohort 2: Ewings Sarcoma Secondary CohortCohort 3: Ewings Sarcoma Expanded CohortCohort 4: OsteosarcomaCohort 5: Synovial SarcomaCohort 6: RhabdomyosarcomaCohort 7a: Alveolar Soft Part SarcomaCohort 7b: Desmoplastic Small Round Cell TumorsCohort 7c: Extraskeletal Myxoid ChondrosarcomaCohort 7d: Clear Cell SarcomaCohort 7e: Myxoid LiposarcomaCohort 8: Diagnosis Not Specified
FatigueGeneral disorders19/7022/541/713/403/2514/415/235/145/115/95/123/11
CoughRespiratory, thoracic and mediastinal disorders7/7010/540/79/405/253/416/230/146/113/91/121/11
HyperglycaemiaMetabolism and nutrition disorders12/709/540/75/404/254/414/233/145/112/90/120/11
NauseaGastrointestinal disorders9/7020/540/77/405/2510/416/231/142/114/93/123/11
HeadacheNervous system disorders10/7017/540/74/400/257/415/233/141/111/91/124/11
AstheniaGeneral disorders5/709/540/74/400/252/412/230/140/111/90/124/11
ConstipationGastrointestinal disorders12/7010/540/77/402/253/413/233/143/113/92/121/11
Pain in extremityMusculoskeletal and connective tissue disorders5/705/540/75/401/250/411/231/141/113/91/122/11
HaemoglobinInvestigations1/701/540/70/400/250/410/230/140/113/90/120/11
DiarrhoeaGastrointestinal disorders11/7015/540/78/403/256/417/231/143/110/92/120/11

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort 1: Ewings Sarcoma Primary CohortCohort 2: Ewings Sarcoma Secondary CohortCohort 3: Ewings Sarcoma Expanded CohortCohort 4: OsteosarcomaCohort 5: Synovial SarcomaCohort 6: RhabdomyosarcomaCohort 7a: Alveolar Soft Part SarcomaCohort 7b: Desmoplastic Small Round Cell Tumors.Cohort 7c: Extraskeletal Myxoid ChondrosarcomaCohort 7d: Clear Cell SarcomaCohort 7e: Myxoid LiposarcomaCohort 8: Diagnosis Not SpecifiedTotal
Mean27 ± 10.7228.3 ± 12.913.3 ± 3.1533.8 ± 18.8341.7 ± 16.1126.5 ± 12.2131.7 ± 13.6723.1 ± 6.0960.9 ± 11.2726.9 ± 11.0150.6 ± 11.0630.7 ± 18.5631.2 ± 13.36
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Ewings Sarcoma Primary CohortCohort 2: Ewings Sarcoma Secondary CohortCohort 3: Ewings Sarcoma Expanded CohortCohort 4: OsteosarcomaCohort 5: Synovial SarcomaCohort 6: RhabdomyosarcomaCohort 7a: Alveolar Soft Part SarcomaCohort 7b: Desmoplastic Small Round Cell Tumors.Cohort 7c: Extraskeletal Myxoid ChondrosarcomaCohort 7d: Clear Cell SarcomaCohort 7e: Myxoid LiposarcomaCohort 8: Diagnosis Not SpecifiedTotal
Female202232011181213233118
Male5032420142311138798199
08

Study locations

41 sites
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • UCLA School Of Medicine Mattel's Children's Hospital At UCLA; Division Of Hematology-Oncology
    Los Angeles, California 90095-1752, United States
  • Sarcoma Oncology Center
    Santa Monica, California 90403, United States
  • Stanford Comprehensive Cancer Center
    Stanford, California 94305, United States
  • Washington Cancer Institute; Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • Kootenai Medical Center
    Coeur d'Alene, Idaho 83814, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • NIH/NCI
    Bethesda, Maryland 20892, United States
  • Massachusetts General Hospital; Dana Farber Partnes Cancer Center
    Boston, Massachusetts 02114, United States
  • Dana Farber Partners Can Ctr
    Boston, Massachusetts 02115-6084, United States
  • University of Michigan Comprehensive Cancer Center
    Ann Arbor, Michigan 48109, United States
  • Nebraska Methodist Hospital; Onc Hem West
    Omaha, Nebraska 68114, United States
  • Albert Einstein College of Medical Pediatrics; Department of Pediatrics
    Bronx, New York 10467, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • Carolinas Hematology Oncology Associates; Investigational Drug Services - Pharmacy
    Charlotte, North Carolina 28203, United States
  • Oregon Health and Science University Cancer Institute
    Portland, Oregon 97239, United States
  • Pennsylvania Oncology Hema Asc
    Philadelphia, Pennsylvania 19106, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Texas Children's Cancer Center; Baylor College of Medicine
    Houston, Texas 77030, United States
  • University of Texas M.D. Anderson Cancer Center
    Houston, Texas 77030, United States
  • Huntsman Cancer Institute; Orthopedic Center
    Salt Lake City, Utah 84112, United States
  • Peter Maccallum Cancer Institute; Medical Oncology
    Melbourne, Victoria 3000, Australia
  • BCCA-Vancouver Cancer Centre
    Vancouver, British Columbia V5Z 4E6, Canada
  • Institut Bergonie; Oncologie
    Bordeaux, 33076, France
  • Centre Oscar Lambret; Chir Cancerologie General
    Lille, 59000, France
  • Centre Leon Berard; Departement Oncologie Medicale
    Lyon, 69373, France
  • Institut Curie; Oncologie Medicale
    Paris, 75231, France
  • Institut Gustave Roussy; Service Pediatrique
    Villejuif, 94805, France
  • HELIOS Klinikum Bad Saarow; Klinik für Innere Medizin III
    Bad Saarow, 15526, Germany
  • Uniklinik Mannheim; Sektion Chirurgische Onkologie & Thoraxchirurgie
    Mannheim, 68167, Germany
  • University Hospital Tübingen
    Tübingen, 72076, Germany
  • Istituti Ortopedici Rizzoli
    Bologna, Emilia-Romagna 40136, Italy
  • Istituto Nazionale Tumori, Sarcoma Unit
    Milano, Lombardia 20133, Italy
  • Erasmus Mc - Daniel Den Hoed Kliniek; Medical Oncology
    Rotterdam, 3015 CE, Netherlands
  • Norwegian Radium Hospital
    Oslo, 0310, Norway
  • Hospital Sant Joan De Deu
    Esplugues De Llobregas, Barcelona 08950, Spain
  • Skånes University Hospital, Skånes Department of Onclology
    Lund, 221 85, Sweden
  • UCL Hospital NHS Trust
    London, NW1 2PG, United Kingdom
  • Royal Marsden Hospital; Dept of Med-Onc
    London, SW3 6JJ, United Kingdom
  • Christie Hospital NHS Trust
    Manchester, M20 4BX, United Kingdom
09

References and documents

Publications

  • Asmane I, Watkin E, Alberti L, Duc A, Marec-Berard P, Ray-Coquard I, Cassier P, Decouvelaere AV, Ranchere D, Kurtz JE, Bergerat JP, Blay JY. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur J Cancer. 2012 Nov;48(16):3027-35. doi: 10.1016/j.ejca.2012.05.009. Epub 2012 Jun 7. PubMed 22682017 ↗
  • Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, Toner GC, Maki RG, Meyers PA, Chugh R, Ganjoo KN, Schuetze SM, Juergens H, Leahy MG, Geoerger B, Benjamin RS, Helman LJ, Baker LH. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol. 2011 Dec 1;29(34):4541-7. doi: 10.1200/JCO.2010.34.0000. Epub 2011 Oct 24. PubMed 22025149 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2007 to primary completion in Feb 2014, 74 months.

Results were first posted in Feb 2021, 6 years 11 months after primary completion. A results delay was requested in Nov 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2008
First posted
Mar 25, 2008
StartActual
Dec 18, 2007
Primary completionActual
Feb 19, 2014
CompletionActual
Feb 19, 2014
Results delay requested
Nov 2, 2016
Results first posted
Feb 3, 2021
Last update
Feb 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00642941
Lead sponsor
Hoffmann-La Roche
Collaborators
Sarcoma Alliance for Research through Collaboration
Responsible party
Sponsor
First posted
Mar 25, 2008
Start date
Dec 18, 2007
Primary completion
Feb 19, 2014
Completion
Feb 19, 2014
Results posted
Feb 3, 2021
Last update
Feb 3, 2021

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teprotumumab

Start the discussion